Literature DB >> 24662003

Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis.

Tae-Joon Kim1, Soon-Tae Lee2, Jung-Won Shin1, Jangsup Moon1, Jung-Ah Lim1, Jung-Ick Byun1, Yong-Won Shin1, Keon-Joo Lee1, Keun-Hwa Jung1, Young-Soo Kim3, Kyung-Il Park4, Kon Chu1, Sang Kun Lee1.   

Abstract

Encephalitis associated with anti-γ-aminobutyric acid-B (GABAB) receptor antibodies has been identified recently. However, only a few cases have been reported to date and its clinical manifestations and prognosis have not been investigated systematically. We identified five cases of GABAB encephalitis in Korea. Here we present the clinical features, treatment responses, and brain positron emission tomography findings of the cases. The patients had a clinical triad of memory changes, seizure, and association with small-cell lung cancer. Early diagnosis and comprehensive immune modulation may provide a good outcome.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune synaptic encephalitis; Encephalitis; GABA(B)

Mesh:

Substances:

Year:  2014        PMID: 24662003     DOI: 10.1016/j.jneuroim.2014.02.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

Review 1.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 2.  Autoimmune encephalopathies.

Authors:  Frank Leypoldt; Thaís Armangue; Josep Dalmau
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 3.  Progress in autoimmune epileptic encephalitis.

Authors:  Sukhvir Wright; Angela Vincent
Journal:  Curr Opin Neurol       Date:  2016-04       Impact factor: 5.710

4.  Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

Authors:  Woo-Jin Lee; Soon-Tae Lee; Jangsup Moon; Jun-Sang Sunwoo; Jung-Ick Byun; Jung-Ah Lim; Tae-Joon Kim; Yong-Won Shin; Keon-Joo Lee; Jin-Sun Jun; Han Sang Lee; Soyun Kim; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Manho Kim; Sang Kun Lee; Kon Chu
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 5.  Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies.

Authors:  Matteo Gastaldi; Anaïs Thouin; Angela Vincent
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  The Laboratory Diagnosis of Autoimmune Encephalitis.

Authors:  Sang Kun Lee; Soon-Tae Lee
Journal:  J Epilepsy Res       Date:  2016-12-31

7.  Gamma-aminobutyric acid-B limbic encephalitis and asystolic cardiac arrest: a case report.

Authors:  Christopher A Ovens; Angelo Jayamanne; Andrew Duggins
Journal:  J Med Case Rep       Date:  2017-12-29

Review 8.  Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions.

Authors:  James Varley; Angela Vincent; Sarosh R Irani
Journal:  J Neurol       Date:  2014-12-10       Impact factor: 4.849

9.  GABAB Encephalitis: A Fifty-Two-Year-Old Man with Seizures, Dysautonomia, and Acute Heart Failure.

Authors:  Matthew C Loftspring; Eric Landsness; Lindsey Wooliscroft; Robert Rudock; Sally Jo; Kevin R Patel
Journal:  Case Rep Neurol Med       Date:  2015-11-02

10.  Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study.

Authors:  Jung-Ick Byun; Soon-Tae Lee; Keun-Hwa Jung; Jun-Sang Sunwoo; Jangsup Moon; Jung-Ah Lim; Doo Young Lee; Yong-Won Shin; Tae-Joon Kim; Keon-Joo Lee; Woo-Jin Lee; Han-Sang Lee; Jinsun Jun; Dong-Yub Kim; Man-Young Kim; Hyunjin Kim; Hyeon Jin Kim; Hong Il Suh; Yoojin Lee; Dong Wook Kim; Jin Ho Jeong; Woo Chan Choi; Dae Woong Bae; Jung-Won Shin; Daejong Jeon; Kyung-Il Park; Ki-Young Jung; Kon Chu; Sang Kun Lee
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.